News
Article
Roquette Acquires Itacel
Author(s):
Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.
On Sept. 1, 2017, Roquette, a French biopharmaceutical company specializing in plant-based excipients, completed the previously announced acquisition of Itacel. Itacel is an excipient division of Blanver, a Brazilian multinational company specializing in the development, manufacture, and commercialization of raw materials and drugs.
The acquisition is part of a series of investments made by Roquette to position itself globally, according to the company. Financial details of the closing are unpublicized.
Source: Roquette
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
